Mitchell Keegan Selected Research

defactinib

1/2020	Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
1/2016	A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mitchell Keegan Research Topics

Disease

3	Neoplasms (Cancer) 01/2016 - 12/2007
2	Disease Progression 01/2020 - 01/2016
1	Fatigue 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020

Drug/Important Bio-Agent (IBA)

2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2020 - 01/2016
2	defactinibIBA 01/2020 - 01/2016
1	BilirubinIBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 05/2010
1	7- (4- (3- ethynylphenylamino)- 7- methoxyquinazolin- 6- yloxy)- N- hydroxyheptanamideIBA 05/2010
1	Pharmaceutical PreparationsIBA 05/2010
1	Histone Deacetylases (Histone Deacetylase)IBA 05/2010
1	Phosphotransferases (Kinase)IBA 05/2010
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2010
1	human ERBB2 proteinIBA 05/2010
1	KinesinsIBA 12/2007
1	Chlorpromazine (Thorazine)FDA Link 12/2007

Therapy/Procedure

2	Therapeutics 05/2010 - 12/2007